© 1996 American Heart Association, Inc.
Articles |
Fibrinogen Is a Predictor of Mortality in Coronary Heart Disease Patients
From the BIP Coordinating Center, Neufeld Cardiac Research Institute, Sheba Medical Center (M.B., H.R.-R., S.B., U.G.), Tel-Hashomer, Israel, and Central Laboratory, Edith Wolfson Medical Center (E.G., D.B.), Holon, Israel.
Correspondence to Michal Benderly, BIP Coordinating Center, Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer 52621 Israel. E-mail bender@ccsg.tau.ac.il.
Abstract Results of epidemiological studies have indicated that fibrinogen is an important primary cardiovascular risk factor. The role of fibrinogen as a predictor of mortality in coronary heart disease (CHD) patients is unclear. We investigated the association between fibrinogen and mortality in a large cohort of CHD patients screened for participation in a secondary prevention clinical trial. Of the total investigated, 3092 men who were not included in the trial and for whom vital status was known were followed up for a mean period of 3.2 years. In 54.4% of the 111 men who died, mortality was attributed to CHD. Mean baseline plasma fibrinogen levels were 29.4 mg/dL higher in patients who died than in the survivors. All-cause and CHD mortality rates increased with increasing fibrinogen levels. This relationship was also demonstrated within categories of the primary variables predicting mortality in these patients. The contribution of fibrinogen to CHD and all-cause mortality was assessed by multivariate analysis adjusting for age, CHD severity, and comorbidity. Risks of CHD and all-cause mortality for patients in the highest fibrinogen tertile were 1.67 and 1.75, respectively, relative to patients in the lowest tertile, and an increase of about 1 SD of plasma fibrinogen level (75 mg/dL) was found to increase risk of CHD and all-cause mortality by 29% and 31%, respectively. These results indicate clearly that fibrinogen level is associated with significantly increased mortality in CHD patients. Implementation of a standardized measuring method is required to allow assessment of risk in CHD patients on the basis of fibrinogen levels.
Key Words: fibrinogen • coronary disease • risk factors • mortality • prospective study
This article has been cited by other articles:
 |
|
 |
|
  J. L. Mega, D. A. Morrow, J. A. de Lemos, S. Mohanavelu, C. P. Cannon, and M. S. Sabatine Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2422 - 2429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Ganotakis, I. F. Gazi, J. A. Papadakis, I. A. Jagroop, D. R. Nair, and D. P. Mikhailidis The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 35 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Vlachopoulos, K. Aznaouridis, N. Ioakeimidis, K. Rokkas, C. Vasiliadou, N. Alexopoulos, E. Stefanadi, A. Askitis, and C. Stefanadis Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease Eur. Heart J., November 2, 2006; 27(22): 2640 - 2648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ziakas, S. Gavrilidis, G. Giannoglou, E. Souliou, K. Gemitzis, D. Kalampalika, M. A. Vayona, I. Pidonia, G. Parharidis, and G. Louridas In-Hospital and Long-Term Prognostic Value of Fibrinogen, CRP, and IL-6 Levels in Patients with Acute Myocardial Infarction Treated with Thrombolysis Angiology, May 1, 2006; 57(3): 283 - 293. [Abstract] [PDF]
|
|
|
|
 |
|
 Fibrinogen Studies Collaboration* Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality: An Individual Participant Meta-analysis JAMA, October 12, 2005; 294(14): 1799 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Papadakis, D. P. Mikhailidis, G. E. Vrentzos, A. Kalikaki, I. Kazakou, and E. S. Ganotakis Effect of Antihypertensive Treatment on PlasmaFibrinogen and Serum HDL Levelsin Patients with Essential Hypertension Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 139 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 A S T Bickerton, N Clark, D Meeking, K M Shaw, M Crook, P Lumb, C Turner, and M H Cummings Cardiovascular risk in women with polycystic ovarian syndrome (PCOS) J. Clin. Pathol., February 1, 2005; 58(2): 151 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haim, V. Boyko, U. Goldbourt, A. Battler, and S. Behar Predictive Value of Elevated White Blood Cell Count in Patients With Preexisting Coronary Heart Disease: The Bezafibrate Infarction Prevention Study Arch Intern Med, February 23, 2004; 164(4): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Stangl, G. Baumann, and K. Stangl Coronary atherogenic risk factors in women Eur. Heart J., November 2, 2002; 23(22): 1738 - 1752. [Full Text] [PDF]
|
|
|
|
|
|
M. Haim, D. Tanne, V. Boyko, T. Reshef, U. Goldbourt, J. Leor, Y. A. Mekori, and S. Behar Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease: Data from the Bezafibrate Infarction Prevention (BIP) Study J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1133 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Palmieri, A. Celentano, M. J. Roman, G. de Simone, M. R. Lewis, L. Best, E. T. Lee, D. C. Robbins, B. V. Howard, and R. B. Devereux Fibrinogen and Preclinical Echocardiographic Target Organ Damage: The Strong Heart Study Hypertension, November 1, 2001; 38(5): 1068 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Liu, N Saha, C K Heng, S Hong, and P S Low Fibrinogen genotypes ({alpha} and {beta}) are associated with plasma fibrinogen levels in Chinese J. Med. Genet., September 1, 2001; 38(9): e31 - 31. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Napoli, F. Papa, and V. Bocola Prognostic Influence of Increased C-Reactive Protein and Fibrinogen Levels in Ischemic Stroke Stroke, January 1, 2001; 32(1): 133 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.B Smith, F.G.R Fowkes, A Rumley, A.J Lee, G.D.O Lowe, and C.M Hau Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study Eur. Heart J., October 1, 2000; 21(19): 1607 - 1613. [Abstract] [PDF]
|
|
|
|
 |
|
 C. T. Park and S. D. Wright Fibrinogen is a component of a novel lipoprotein particle: Factor H-related protein (FHRP)-associated lipoprotein particle (FALP) Blood, January 1, 2000; 95(1): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Maresca, A. Di Blasio, R. Marchioli, and G. Di Minno Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction : An Update Arterioscler Thromb Vasc Biol, June 1, 1999; 19(6): 1368 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tenenbaum, E. Z. Fisman, V. Boyko, U. Goldbourt, E. Graff, J. Shemesh, A. Shotan, H. Reicher-Reiss, S. Behar, and M. Motro Hypertension in Diet Versus Pharmacologically Treated Diabetics : Mortality Over a 5-Year Follow-Up Hypertension, April 1, 1999; 33(4): 1002 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eriksson, N. Egberg, S. Wamala, K. Orth-Gomer, M. A. Mittleman, and K. Schenck-Gustafsson Relationship Between Plasma Fibrinogen and Coronary Heart Disease in Women Arterioscler Thromb Vasc Biol, January 1, 1999; 19(1): 67 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Danesh, R. Collins, P. Appleby, and R. Peto Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease: Meta-analyses of Prospective Studies JAMA, May 13, 1998; 279(18): 1477 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Toss, B. Lindahl, A. Siegbahn, L. Wallentin, and f. t. F. S. Group Prognostic Influence of Increased Fibrinogen and C-Reactive Protein Levels in Unstable Coronary Artery Disease Circulation, December 16, 1997; 96(12): 4204 - 4210. [Abstract] [Full Text]
|
|
|
|
|
|
M. Frohlich, M. Sund, S. Russ, A. Hoffmeister, H. G. Fischer, V. Hombach, and W. Koenig Seasonal Variations of Rheological and Hemostatic Parameters and Acute-Phase Reactants in Young, Healthy Subjects Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2692 - 2697. [Abstract] [Full Text]
|
|